Verus Pharmaceuticals, Inc. sold its pediatric asthma development programs to AstraZeneca. This includes the North American rights to a Captisol enabled budesonide solution (controller medication), a short-acting beta agonist solution (rescue medication), a customized version of eFlow (novel nebulizer delivery device) for use with both medications, and other intellectual property and related assets from Verus. Under the terms of the agreement, Verus will receive an upfront payment of $30 mi...